Holding(s) in Company

RNS Number : 7967W

AstraZeneca PLC

03 February 2012

 



Disclosure and Transparency Rule 5.8.12

Notification of major interest in shares

On 2 February 2012, Investor AB notified the Company that, on 1 February 2012, its interest in the US$0.25 ordinary shares of the Company (the "Shares") had gone above a whole percentage point threshold to 4.02%.

The number of Shares, and voting rights, held by Investor AB remains unchanged at 51,587,810 and the increase in the percentage is due to the decrease in the number of Shares in issue as notified by the Company in its monthly voting rights and capital disclosure on 1 February 2012.

The full notification from Investor AB is set out below.

A C N Kemp

Company Secretary

3 February 2012

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:			AstraZeneca PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	A change in the total voting rights notified by AstraZeneca PLC on 1 February 2012			P
3. Full name of person(s) subject to the notification obligation:		Investor AB
4. Full name of shareholder(s)  (if different from 3.):		N/A
5. Date of the transaction and date on which the threshold is crossed or reached:		1 February 2012
6. Date on which issuer notified:		2 February 2012
7. Threshold(s) that is/are crossed or reached:		Holding increased to above 4%, from above 3%

8. Notified details:

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of  voting rights

Direct

Direct

Indirect

Direct

Indirect

Ordinary Shares of $0.25 each

51,587,810

51,587,810

51,587,810

51,587,810

N/A

4.02%

N/A

ISIN - GB0009895292

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

N/A

N/A

N/A

N/A

N/A

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights

N/A

N/A

N/A

N/A

N/A

Nominal

Delta

N/A

N/A

Total (A+B+C)

Number of voting rights

Percentage of voting rights

51,587,810

4.02%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
N/A
Proxy Voting:
10. Name of the proxy holder:		N/A
11. Number of voting rights proxy holder will cease to hold:		N/A
12. Date on which proxy holder will cease to hold voting rights:		N/A
13. Additional information:	This notification has been prepared using the total voting rights figure of 1,283,229,265 ordinary shares as set out in the public announcement made by AstraZeneca PLC on 1 February 2012
14. Contact name:	Martin Bennett - Assistant Company Secretary
15. Contact telephone number:	020 7604 8157

 

END

 

 

HOLBUGDDSBGBGDX